Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Zaini



Author of

  • +

    P2.03 - Chemotherapy/Targeted Therapy (ID 704)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P2.03-031 - Efficacy of Gefitinib and Radiotherapy Combination in Lung Adenocarcinoma (ID 9160)

      09:30 - 09:30  |  Author(s): J. Zaini

      • Abstract

      Background:
      Combinations of gefitinib and radiotherapy have been observed to have synergistic and anti-proliferative effects on lung cancer in vitro, but clinical studies were limited. In clinical setting, patients who presented with respiratory difficulties like SVCS, radiotherapy should be given immediately to address the emergency while waiting for the results of EGFR mutation test.

      Method:
      We did a preliminary study to evaluate the efficacy of gefitinib and radiotherapy combination in lung adenocarcinoma in Persahabatan National Respiratory Refferal Hospital Jakarta Indonesia. Subjects were consecutively recruited between January 2013 to December 2016

      Result:
      Thirty one lung adenocarcinoma with EGFR mutations were enrolled. Most of them were male (51.61%) with median age of 54.5 years old (range 38-70 years old). Epidermal Growth Factor Reseptor (EGFR) mutation characteristics were on exon 21 L858R (61.30%); exon 21 L861Q (16.12%) and exon 19 deletion (22.58%). Radiotherapy were given at doses between 30-60 Gy. Among these subjects, Progression Free Survival (PFS) were 185 days (CI95%; 123.69-246.30), 1 year survival rate (1-ysr) was 45.2%. and overall survival (OS) are 300 days (CI95%;130.94-469.06). There were no grade 3/4 hematological and non hematological toxicities recorded. The most frequent Grade 1 and 2 non hematological toxicities were skin rash, diarrhea, paranochia and monoliasis and might be related to TKI.

      Conclusion:
      The combination of TKI with radiation may be considered in subjects with respiratory distress.

  • +

    P3.11 - Patient Advocacy (ID 727)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Patient Advocacy
    • Presentations: 1
    • +

      P3.11-001 - Factors Correlated With Time and Cost Diagnostic Lung Cancer (ID 10138)

      09:30 - 09:30  |  Author(s): J. Zaini

      • Abstract

      Background:
      Most of lung cancer patients diagnosed in advanced stage. The reasons for the delay of the diagnosis might be from patient and/or health care system. Currently, Indonesia, as a developing country in Asia, has National Health Insurance System (Jaminan Kesehatan Nasional) of which the patients is feasibly referred to the referral hospital without worrying the cost. In Persahabatan Hospital-the National Referral for Respiratory Diseases many cases have diagnostic delayed that might contribute to the prognosis. We had been conducting a study to evaluate diagnostic time and diagnostic cost to diagnose lung cancer.

      Method:
      We conducted an observational study in Persahabatan Hospital Jakarta of which newly diagnosed lung cancer patients were reviewed. We evaluated the time and cost needed from the first visit until definitive diagnosis by histopatology obtained. We also evaluated the factors that have correlated with time and cost of lung cancer diagnosis.

      Result:
      One hundred and ten subjects were enrolled in this study. Eighty four (76,36%) were male and 26 (23,64%) were female. The median age was 57 years old with range 26 to 86 years old. Data have shown that 53 (48,2%) subjects were diagnosed under target time ( less than 2 weeks) but 57 subjects (51,8%) had diagnostic time more than 2 weeks. The median time of diagnostic was 15 days with the range of 1 to 68 days. Diagnostic delay was correlated with: early stage of the diseases, good performance status, no financial resource. The median cost of diagnosis was 13.025.381 Rupiahs ( around 1000 US$) with range Rp. 1.083.000,- to Rp156.285.000,- ( <100US$ to 11.000 US$). Subject who came with advanced stage, poor performance status, had complication of lung cancer and reffered to private hospitals had higher diagnostic cost.

      Conclusion:
      Median diagnostic time of lung cancer in Persahabatan Hospital Jakarta Indonesia was 15 days ranging from 1 to 86 days. Diagnostic time correlated with stage at admission, performance status at admission and financial support. The median cost of diagnosis was Rp. 13.025.381,- ( around 1000 US$) with the range of Rp. 1.083.000,- to Rp156.285.000,- ( < 100US$ to 10.000 US$). Cost of lung cancer diagnosis correlated with stage at admission, performance status at admission, source of financial support and complication related to lung cancer.